Differences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIV(mac251) infection of rhesus macaques; a pilot study by Stevceva, Liljana et al.
BMC Infectious Diseases (2001) 1:9 http://www.biomedcentral.com/1471-2334/1/9
BMC Infectious Diseases (2001) 1:9 Research article
Differences in time of virus appearance in the blood and virus-
specific immune responses in intravenous and intrarectal primary 
SIVmac251 infection of rhesus macaques; a pilot study
Liljana Stevceva1, Elzbieta Tryniszewska1, Zdenek Hel1, Janos Nacsa1, 
Brian Kelsall2, Robyn Washington Parks1 and Genoveffa Franchini*1
Address:  1Basic Research Laboratory, National Cancer Institute, 41/D804, Bethesda, Maryland, 20892, USA and 2Laboratory of Clinical 
Investigation, National Institute of Allergy and Infectious Diseases, 10/11N238, Bethesda, MD, 20892-1890, USA
E-mail: Liljana Stevceva - stevcevl@mail.nih.gov; Elzbieta Tryniszewska - et74h@nih.gov; Zdenek Hel - zdenek@helix.nih.gov; 
Janos Nacsa - nacsa@nih.gov; Brian Kelsall - bk19v@nih.gov; Robyn Washington Parks - ParksR@intra.nci.nih.gov; 
Genoveffa Franchini* - veffa@helix.nih.gov
*Corresponding author
Abstract
Background:  HIV-I can be transmitted by intravenous inoculation of contaminated blood or
blood product or sexually through mucosal surfaces. Here we performed a pilot study in the
SIVmac251 macaque model to address whether the route of viral entry influences the kinetics of the
appearance and the size of virus-specific immune in different tissue compartments.
Methods:   For this purpose, of 2 genetically defined Mamu-A*01-positive macaques, 1 was
exposed intravenously and the other intrarectally to the same SIVmac251 viral stock and virus-
specific CD8+ T-cells were measured within the first 12 days of infection in the blood and at day
12 in several tissues following euthanasia.
Results:  Virus-specific CD8+ T-cell responses to Gag, Env, and particularly Tat appeared earlier
in the blood of the animal exposed by the mucosal route than in the animal exposed intravenously.
The magnitude of these virus-specific responses was consistently higher in the systemic tissues and
GALT of the macaque exposed by the intravenous route, suggesting a higher viral burden in the
tissues as reflected by the faster appearance of virus in plasma. Differences in the ability of the virus-
specific CD8+ T-cells to respond in vitro to specific peptide stimulation were also observed and the
greatest proliferative ability was found in the GALT of the animal infected by the intrarectal route.
Conclusions:  These data may suggest that the natural mucosal barrier may delay viral spreading.
The consequences of this observation, if confirmed in studies with a larger number of animals, may
have implications in vaccine development.
Background
Infection with human immunodeficiency vims (HIV)
elicits an acute retroviral syndrome characterized by fe-
ver, pharyngitis, lymphadenopathy, myalgia, rash, and
headache [1,2,3]. Sexual transmission of HIV infection
occurs mostly via the intestinal or vaginal mucosa but
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HIV-I is also effectively transmitted by the intravenous
route [4] [5,6,7].
Recent studies have shown that the HIV-I or SIV virus
rapidly penetrates vaginal, rectal, or oral mucosa attach-
ing to and infecting primarily CD4+ T-cells where it rep-
licates and consequently spreads to lymphoid tissue and
systemic organs [8] [9,10,11,12].
Accumulating evidence has implicated virus-specific
CTL in containing primary HIV/SIV infection and HIV-
I/SIV-specific CD8+ CTL have been documented during
the early weeks following infection, before a neutralizing
Ab response is demonstrable [13] [14,15,16]. Despite the
rapid dissemination of HIV-I by mucosal routes, produc-
tive mucosal transmission appears to be relatively ineffi-
cient and is estimated to occur once in 300 or more high-
risk exposures [17]. Cell-mediated immunity and direct
killing by cytotoxic lymphocytes from the vagina and co-
lon lamina propria may be an important factor in con-
taining viral infection at the site of primary infection [18]
[19,20].
Mucosal T lymphocytes appear to be functionally distinct
from those present in the peripheral circulation. While
activated T-cells reenter lymphoid tissues and preferen-
tially accumulate at the site of the initial activation,
memory T-cells migrate continuously and randomly,
similar to naive T-cells [21] [22]. The implication in
terms of HIV infection is that, in the initial phase of an
immune response, once primed, Ag-specific memory T-
cells randomly enter and leave various lymphoid com-
partments but preferentially are retained in the lym-
phoid compartment where the antigen was presented at
first [23] [24].
In humans, it is unfeasible to evaluate the immunologi-
cal events that occur shortly after infection in the mucos-
al compartments. However, in the SIVmac251 macaque
model, some of these issues can be addressed. SIVmac251
establishes persistent infection in rhesus macaques and
causes an immunodeficiency syndrome closely resem-
bling human AIDS [25] [26,27,28]. As in humans, the
clinical course of SIVmac251 infection varies considerably
among macaques. Recent evidence from our lab suggests
that macaques that express the major histocompatibility
class I Mamu-A*01 molecule restrict SIVmac251 replica-
tion following intrarectal exposure, as reported for HIV-
I-infected individuals that express the HLA B*5701 [29],
further validating this animal model of HIV-I infection.
In this model, virus strain, dose, and especially route of
infection can be defined and host-virus interactions un-
der different conditions can be assessed. Here we used
genetically defined Mamu-A*01 rhesus macaques to
study the extent of virus-specific CD8+ T-cell response
and the trafficking of lymphocytes to the gut during the
first 12 days of intrarectal or intravenous transmission of
the same stock of SIVmac251.
Materials
Animals and procedure
Two female Mamu-A*01-positive macaques were in-
volved in this study: animal 817 that was infected by un-
diluted SIVmac251/561 stock virus (R. Pal et al.,
unpublished data) by the intrarectal route and animal
819 by the intravenous route with a 1:3000 dilution of
the same viral stock. Blood was drawn before infection
and at days 4, 8, and 12 after inoculation with the virus.
Animals were sacrificed at day 12 postinfection. The
spleens and hilar, axillary, mesenteric, iliac, and inguinal
lymph nodes as well as ileums, jejunums, and colons
were collected in RPMI medium containing 10% FCS+
penicillin/streptomycin.
Isolation of tissue lymphocytes
Mononuclear cells were isolated from peripheral blood
(PBMC), lymph nodes, spleens, and intestines. Mono-
nuclear cells from spleens and lymph nodes were isolat-
ed by mechanical dissociation of the tissue and
consecutive Ficoll gradient centrifugation. Tissues from
ileums, jejunums, and colons were treated with 1 mM
DTT (ICN Biomedicals, Aurora, OH) for 30 minutes
followed by incubation in calcium/magnesium-free
HBSS with EDTA (Life Technologies, Baltimore, MD) 4
times 1 hour with stirring at room temperature to remove
the epithelial layer. At this stage, pieces of tissue were
fixed in 10% neutral formalin and embedded in paraffin
and sections were cut and stained with H&E. Microscop-
ic examination was performed to ensure that all of the
epithelium was removed and the lamina propria was in-
tact.
Further, tissues were cut into smaller pieces and incubat-
ed at 37°C in Isocove's medium supplemented with 10%
fetal calf serum and penicillin/streptomycin containing
400 U/ml Collagenase D (Boerrhinghem & Mannheim
GmbH, Mannheim, Germany) and 25 U/ml DNAse
(Worthington Biochemical, Lakewood, NJ) for 2–3
hours. The mononuclear cells were isolated from the su-
pernatant containing dissociated cells by Percoll gradi-
ent centrifugation.
Flow cytometry
Fresh mononuclear cells were directly stained with PE-
conjugated tetrameric complexes for Gag 181, Env 622,
and Tat 28. PerCP-conjugated anti-CD3e (Pharmingen,
San Diego, CA) and FITC-conjugated anti-CD8 (Becton
Dickinson, San Jose, CA) were used in conjunction with
the tetrameric complexes. In addition, cells were stained
with a combination of anti-CD3 PerCP, anti-CD8 FITCBMC Infectious Diseases (2001) 1:9 http://www.biomedcentral.com/1471-2334/1/9
and anti CD4 PE (Becton Dickinson, San Jose, CA) . To
assess their proliferative ability and to confirm the spe-
cificity of tetramer staining of ex vivo CD3+ CD8+ T-
cells, lymphocytes were cultured at a concentration of 3
×  106/ml in RPMI enriched with 10% human serum with
addition of 10 µg/ml of the appropriate peptide and 20
U/ml of IL-2 for 7 days. Staining with tetrameric com-
plexes was done afterward as described above.
Briefly, 5 ×  l05 lymphocytes isolated by Ficoll diatrizoate
or Percoll gradient centrifugation were incubated with
tetrameric complexes as previously described [30] and/
or selected Ab for 30 minutes at room temperature. After
washing the cells twice in Dulbecco's phosphate buffered
saline supplemented with 2% FCS and fixation in 1%
paraformaldehyde (Ph = 7.4), samples were analyzed by
flow cytometry using FACScalibur (Becton Dickinson,
San Jose, CA) instrument.
Viral load (NASBA)
SIVmac251 viral RNA copies in plasma was quantified by
nucleic-acid-sequence-based amplification [31]. Briefly,
RNA extracted from plasma was subjected to isothermal
amplification with SIVmac251-specific primers. A portion
of the SIV wild type Gag gene was used to generate inter-
nal control. NASBA amplification products were detect-
ed by using chemiluminescence-based probe
hybridization system. The assay can measure accurately
Figure 1
Plasma viral RNA appearance and the depletion of CD4+ T-cells were delayed (A) while virus-specific CD8+ T-cell response
appeared earlier (B) in the animal infected intrarectally. The opposite pattern was observed in the animal infected intravenously
(C, D). Plasma viral RNA was detected by NASBA. Total number of CD4+ T-cells was counted in the blood. Virus-specific
CD8+ T-cell response was assessed by tricolor staining with CD3, CD8, and tetrameric complexes to Gag 181, Tat 28, and
Env 622. CD8+ T-cells were defined by gating on CD3+ CD8+ cell population. An equivalent number of cells (1 ×  104) was
acquired through this gate in each analysis performed.BMC Infectious Diseases (2001) 1:9 http://www.biomedcentral.com/1471-2334/1/9
tenfold changes and is functional over a dynamic range
spanning at least 104–107 copies.
Results
Kinetics of viral appearance and CD4+ T-cell decrease in 
the blood
Since the knowledge of the Mamu-A*01-restricted
epitopes [32][33] allows for a quantitation of the CD8+
T-cell response using the tetramer technology [34],
Mamu-A*01 macaques were chosen for this study. Fol-
lowing exposure to the same viral stock of SIVmac251 of
macaque 817 by the intrarectal route and macaque 819
by the intravenous route, the kinetics of viral RNA ap-
pearance in the plasma was assessed by NASBA. Plasma
viral RNA was detected as early as day 8 in animal 819,
exposed by the intravenous route, and was highest at
time of euthanasia (day 12), as demonstrated in Fig. 1C.
In contrast, in animal 817, exposed by the intrarectal
route, the appearance of plasma virus was delayed to day
12 postinfection (Fig. 1A) and at that time plasma viral
RNA was 2 logs lower in animal 817 than in animal 819
(Figs. 1A and 1C). The absolute number of CD4+ T-cells/
mm3 blood decreased by 50% in both macaques by day
12 (Figs. 1A and 1C). However, the absolute number of
CD8+ T-cells and CD3+ T-cells decreased as well, indi-
cating that the apparent depletion of CD4+ T-cells may
be due to redistribution rather than loss of CD4+ T-cells
at this stage of infection.
Since animal 817 received three thousandfold more virus
than animal 819, these data suggest that the kinetics of
viral appearance in the blood in primary SIVmac251 infec-
tion may depend on the route of challenge rather than
dose.
Virus-specific CD8+ T-cell response in the blood
Virus-specific CD8+ T-cells were quantitated in the
blood of both animals at days 0, 4, and 12 postinfection
using 3 tetrameric Mamu-A*01 molecules complexed
with the SIVmac Gag 181, Env 622, and Tat 28 peptides
(T.M. Alien et al., submitted).
In the blood, virus-specific tetramer-binding CD3+
CD8+ T-cells appeared earlier in macaque 817, exposed
to SIVmac251 by the intrarectal route, than in 819 for all
the 3 antigens studied (Figs. 1B and 1D). Overall, the size
of the virus-specific CD8+ T-cell response in the blood
was higher in animal 817 and, interestingly, a large pop-
ulation of Tat-specific CD8+ T-cells appeared in the
blood as early as day 4, whereas in the same animal
CD8+ T-cells specific to Gag 181 and Env 622 peaked lat-
er (Fig. 1). These data are consistent with previous obser-
vations on the kinetics of appearance of virus-specific
CD8+ T-cells that recognize the Tat 28 epitope and un-
derscore the importance of the immune response to this
early SIVmac251 protein [35][36,37].
Figure 2
Depletion of CD4+ T-cells was not observed in tissues of either animal. The CD4+ T-cell population was defined by tricolor
staining for CD3, CD4, and CD8. T-cells were defined by gating through CD3+ cells. An equivalent number of cells (1 ×  104)
was acquired through this gate for each analysis performed.BMC Infectious Diseases (2001) 1:9 http://www.biomedcentral.com/1471-2334/1/9
Figure 3
Tetramer-positive CD8+ T-cells were higher in axillary (A) and mesenteric lymph nodes (C) of the macaque infected intrave-
nously (A, C, D, E, F, and G)12 days postinfection. The CD8+ T-cell population was defined by gating on CD3+ CD8+ lym-
phocyte population (B). The same number of cells (1 ×  104), when possible, was acquired through this gate for every analysis
performed.BMC Infectious Diseases (2001) 1:9 http://www.biomedcentral.com/1471-2334/1/9
Figure 4
Tetramer-positive CD8+ T-cells from jejunum lamina propria (A), colon lamina propria (B), and ileum lamina propria (C) were
higher in animal 819 that was infected intravenously. Figure D and E show the population of tat28+ cells in jejunum lamina pro-
pria of animal 817 (infected intrarectally, D) and animal 819 (infected intravenously, E).BMC Infectious Diseases (2001) 1:9 http://www.biomedcentral.com/1471-2334/1/9
Absence of CD4+ T-cell depletion in the GALT of Mamu-
A*01 macaques
Both macaques were euthanized at day 12 and the rela-
tive percentages of CD4+ and CD8+ T-cells was assessed
in various compartments. In contrast to previous reports
[38] [39], depletion of CD4+ T-cells was not observed in
any tissues, including the GALT of either animal (Fig. 2).
It is possible that both animals could have controlled vi-
ral replication or that the tissues were examined too early
and that depletion would have occurred at a latter stage
of the infection. Preservation of CD4+ T-cell depletion in
the GALT during primary infection may be a key event in
delaying disease progression.
Quantitation of ex vivo CD8+ T-cell response in tissues
Virus-specific Gag 181 CD8+ T-cell response in the blood
of macaques exposed intravenously to SIVmac251 appears
to peak within the first weeks following intravenous ex-
posure [40]. Therefore, both macaques were euthanized
at day 12 and lymphocytes were harvested from several
systemic tissues as well as the GALT. Quantitation of the
ex vivo CD8+ T-cell population specific for Gag, Tat, and
Env in the systemic tissues of both animals revealed that,
in contrast to the blood, the highest virus-specific CD8+
T-cell response was found in most tissues of animal 819,
challenged by the intravenous route (Figs. 3 and 4 and
Table). In the same animal, the percentage of CD8+ T-
cells specific for Tat 28 was as high as 8%, 6%, and 4% in
the axillary and iliac lymph nodes and the spleen, respec-
tively (Fig. 3A and Table). The number of CD8+ T-cells
with different specificities was also higher in animal 819
than 817 in the GALT and particularly in the jejunum and
ileum lamina propria (Figs. 4A,4B,4C) while the size of
these virus-specific responses in the remaining tissues of
both animals did not differ significantly (Table). These
data indicate that both the Gag 181 and Tat 28 responses
Table 1: 
a)
817 819
env tat gag env tat gag
Illiac sublumbar lymph node 0.35 0.91 0.37 0.64 0.91 0.42
Axillar lymph node 0.37 0.77 1.22 1.17 7.81 6.17
Hilar lymph node 0.92 0.74 0.86 1.04 1.16 0.95
Mesenteric lymph node 0.66 1.77 0.96 3.91 4.8 3.32
Inguinal lymph node 0.47 1.32 0.69 1.22 1.04 0.67
b)
817 819
env tat gag env tat gag
PBMC 0.27 0.74 0.84 0.12 0.35 0.24
spleen 0.61 0.60 0.56 0.55 0.23 1.4
c)
817 819
env tat gag env tat gag
Jejunum lamina propria 0.42 0.31 0.54 1.54 1.08 0.86
Ileum lamina propria 0.24 0.47 0.45 1.45 1.21 1.12
Colon lamina propria 0.28 1.17 0.42 2.89 0.73 2.21BMC Infectious Diseases (2001) 1:9 http://www.biomedcentral.com/1471-2334/1/9
are codominant and suggest that the overall higher
CD8+ T-cell response in animal 819 may be related to an
ongoing higher viral replication in the tissues of this an-
imal, as reflected by the higher level of plasma viremia
present at the time of euthanasia.
Differential proliferative ability of tetramer-binding CD8+ 
cells in tissues of animals 817 and 819
Blood, lymph nodes, and lamina propria lymphocytes
were cultured in vitro in the presence of IL-2 and the vi-
rus-specific Gag 181, Tat 28, and Env 622 peptides to as-
sess the ability of the tetramer-positive CD8+ T-cell
population to expand upon antigen stimulation. In our
experimental conditions, expansion of CD8+ T-cells spe-
cific for Tat, Env, and Gag occurred to a comparable ex-
tent in most tissues and was highest in the blood of
animal 819 (Fig. 5B). In animal 817, the ability of virus-
specific CD8+ T-cells to proliferate was highest in the je-
junum and was higher than that observed in the same
compartment in animal 819 (Fig. 5A). The finding that
the highest level of CD8+ T-cells with proliferative ability
was in the lamina propria of the jejunum of animal 817
challenged intrarectally is suggestive of a qualitative dif-
ference of CD8+ T-cells present at the site of induction
and of heterogeneity in the virus-specific CD8+ re-
sponse.
Discussion
The impact that the route of viral entry of HIV/SIV may
have on the virus-specific immune response and control
of viral replication to it is not yet fully understood. Here
we conducted a small pilot study using genetically de-
fined Mamu-A*01 macaques to study the vims-specific
immune response following parenteral or rectal expo-
sure to SIVmac251 This study was designed to begin to in-
vestigate the specificity of the immune response and its
kinetics as well as the kinetics of viral replication accord-
ing to the site of primary exposure and viral entry.
Within the limitation of the small number of animals
used here, the mucosal barrier delayed the appearance of
virus in the plasma whereas the decrease in the absolute
CD4+ T-cell counts was equivalent. In addition, in con-
trast to other reports [41] [38], depletion of CD4+ T-cells
in the GALT at day 12 postinfection was not observed in
either animal regardless of the route of challenge. It is
unclear what is the reason for this finding. It is possible
that both animals could have controlled the infection or
that the tissues were examined too early and that deple-
tion would have occurred at a latter stage of the infection.
The finding of a higher percentage of tetramer-positive
CD8+ T-cells in tissues of macaque 819, infected intrave-
nously, than in animal 817, infected intrarectally, may
reflect a higher rate of viral replication in tissues of this
Figure 5
Proliferative ability of tetramer-binding CD8+ cells is higher at the site of primary virus encounter. Cells were cultured for 7
days in the presence of IL-2 and Gag 181, Tat 28, or Env 622 peptide. The percentage of tetrameric Mamu-A*01/Gag 181; Tat
28; and Env 622 complex binding CD8+ T-cells was established by tricolor staining, as described previously.BMC Infectious Diseases (2001) 1:9 http://www.biomedcentral.com/1471-2334/1/9
animal at the time of sacrifice. Of interest, the intrarectal
route of infection resulted in faster kinetics of appear-
ance of virus-specific CD8+ T-cells, particularly in the
Tat epitope in the blood, indicating the importance of
this immune response early in infection. In the same an-
imal, a higher number of tetramer-specific CD8+ T-cells
able to proliferate in response to all epitopes tested (Gag
181, Tat 28, and Env 622) was found in jejunum lamina
propria than in other tissues. Unfortunately, at present,
it is not possible to assess whether the differences in the
proliferative ability of these cells reflect functional status
and/or differentiation differences (effector versus mem-
ory) or others, in part because markers to define accu-
rately these cells in rhesus macaques are not available.
Conclusions
In conclusion, this study, within the limitation of the
small number of animals used, appears to suggest that
exposure by the mucosal site, a natural barrier to patho-
gens, delays viral appearance in the blood. The differenc-
es in the relative percentage of homing markers may not
necessarily reflect a true qualitative difference in the
overall lymphocyte trafficking related to the mode of vi-
ral encounter and may depend on the time of analysis,
since the kinetic of viral replication was delayed in the
macaque exposed intrarectally. Nevertheless, these data
demonstrate that a short window of opportunity to con-
tain viral infection following mucosal exposure exists
and that potentiating the effectiveness of the mucosal
natural barrier by local immunization may further limit
or halt viral replication. In fact, in a previous study, we
have observed that it appears to be easier to protect vac-
cinated macaques by intrarectal exposure than intrave-
nous exposure to SIV251 [42]. In particular, since a CD8+
T-cell response to Tat appears to be the earliest, this pro-
tein may be a key component of a preventive vaccine, as
suggested by other [35][36,37,43].
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